glp 1 agonist therapy Clinical Focus on GLP-1 Agonists in Type 2 Diabetes Mellitus Managing symptoms with GLP-1 receptor
Description
NASH, Nonalcoholic steatohepatitis
& Clark, A

Compared with the OC group, the liver TG level, total liver TC level and liver weight of the mice in the Lira intervention group were significantly reduced

The results of these trials have consistently demonstrated the cardiovascular benefits associated with GLP-1 receptor agonists including reductions in major adverse cardiovascular events

Biochemically modified for enhanced potency and sustained action, GLP-1 receptor agonists are successfully in clinical use for the treatment of type-2 diabetes, and several GLP-1-based pharmacotherapies are in clinical evaluation for the treatment of obesity
adults have NAFLD, and 20% of people with obesity develop non-alcoholic steatohepatitis, a more serious form of the disease
